HASBROUCK HEIGHTS, N.J., December 12 /CNW/ - Nymox Pharmaceutical
Corporation (NASDAQ: NYMX) reported today an update on recent study results
and development activities for the Company's NX-1207 drug for benign prostatic
hyperplasia (BPH). The results of the recently completed 2 year double blind
follow-up study demonstrated the durable effect of the drug, which is of
fundamental interest and importance to urologists and their patients. The
study was conducted at 24 U.S. sites and involved 103 unselected patients.
"The study showed that many patients required no further treatment for 2
years after a single office visit administration that took 5-10 minutes. That
level of efficacy is superior to known drugs, and NX-1207 has none of the
impotence, loss of libido, retrograde ejaculation, dizziness, fainting,
weakness, breast enlargement, and the rest of the long list of side effects of
other BPH drugs", said Brian Doyle, Global Sales Manager for Nymox.
Nymox has encountered serious interest and several term sheet offers from
potential large pharmaceutical company marketing partners for NX-1207. The
Company is presently involved with furthering the process, as well as due
diligence procedures. The Company is carefully considering its options for
future marketing arrangements for NX-1207.
The results from the 2 year follow-up study of NX-1207 were reported in
the current issue of Urology Times (Dec. 6, 2007) in a report entitled "BPH
treatment offers promising 2-year results". Urology Times is a leading news
source for urologists, with an editorial board of nationally recognized
experts in urology. This was a placebo controlled double blind U.S. trial. The
data showed that a single treatment with NX-1207 produced durable significant
improvement. Statistical analysis of the controlled data showed that the
results for NX-1207 reached statistical significance (p(less than).05) when
the comparison was done to a baseline matched group of placebo controls.
Nymox has recently conducted a formal survey of a group of expert
urologists in the U.S. which has helped the Company to refine its marketing
strategy for NX-1207. Urologists have expressed a strong interest in NX-1207,
and a preference for its route of administration.
There has been wide interest shown by urologists in this new drug, based
on public comments made by doctors at presentations of NX-1207 data at
meetings of the American Urological Association in Boston, Colorado Springs,
Bermuda, and Scottsdale this year. The Company has received a large number of
emails and calls from patients and doctors throughout the U.S. and
internationally, interested in participating in clinical trials and wanting to
learn more about the drug.
"BPH is an under-treated condition. We believe that an effective
treatment, particularly one that is simple to administer in the office and
essentially painless - and which has negligible side effects, in particular no
sexual side effects - will have a great chance to grow the BPH treatment
population. It is estimated that over 100 million men in the G7 countries have
BPH, and yet less than 25% of them receive any treatment at all. That should
dramatically increase if the treatment was more effective and 'user friendly'.
Men prefer not to have surgery, and they would prefer not to take pills every
day of their lives, with frequent sexual side effects, like impotence and loss
of libido", said Mr. Doyle.
More information about Nymox is available at www.nymox.com, email:
email@example.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of 1995
that involve a number of risks and uncertainties. There can be no assurance
that such statements will prove to be accurate and the actual results and
future events could differ materially from management's current expectations.
The conduct of clinical trials and the development of drug products involve
substantial risks and uncertainties and actual results may differ materially
from expectations. Promising early results do not ensure that later stage or
larger scale clinical trials will be successful or will proceed as expected.
Such factors are detailed from time to time in Nymox's filings with the United
States Securities and Exchange Commission and other regulatory authorities.
For further information:
For further information: Nymox Pharmaceutical Corporation Roy Wolvin